Digoxin Suppresses HIV-1 Replication by Altering Viral RNA Processing
Open Access
- 28 March 2013
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLoS Pathogens
- Vol. 9 (3), e1003241
- https://doi.org/10.1371/journal.ppat.1003241
Abstract
To develop new approaches to control HIV-1 replication, we examined the capacity of recently described small molecular modulators of RNA splicing for their effects on viral RNA metabolism. Of the drugs tested, digoxin was found to induce a dramatic inhibition of HIV-1 structural protein synthesis, a response due, in part, to reduced accumulation of the corresponding viral mRNAs. In addition, digoxin altered viral RNA splice site use, resulting in loss of the essential viral factor Rev. Digoxin induced changes in activity of the CLK family of SR protein kinases and modification of several SR proteins, including SRp20 and Tra2β, which could account for the effects observed. Consistent with this hypothesis, overexpression of SRp20 elicited changes in HIV-1 RNA processing similar to those observed with digoxin. Importantly, digoxin was also highly active against clinical strains of HIV-1 in vitro, validating this novel approach to treatment of this infection. Antiretroviral therapies (ART) for HIV/AIDS are successful in slowing disease progression by inhibiting viral proteins. However, the ability of HIV to adapt to ARTs has given rise to drug-resistant virus strains that now represent ≥16% of newly infected people. This development calls for the generation of new treatment strategies. Since HIV is dependent upon RNA processing under control of the host, we searched for compounds/drugs that inhibit HIV-1 replication at this step. We identified digoxin as a potent inhibitor of HIV-1 replication. The drug inhibited expression of HIV-1 structural proteins and a key factor involved in viral RNA export. This response was accomplished by altering the efficiency and splicing choices in HIV-1 RNA processing. Since this stage of the virus lifecycle is not targeted by current ARTs, the digoxin family of drugs represent a novel class of HIV-1 inhibitors. Since digoxin targets host factors and is already in clinical use, it and potentially the cardiac glycoside family of drugs has the possibility for swift development into a new ART for HIV-1 infection.Keywords
This publication has 66 references indexed in Scilit:
- Rapid-Response Splicing Reporter Screens Identify Differential Regulators of Constitutive and Alternative SplicingMolecular and Cellular Biology, 2010
- Role of Cellular RNA Processing Factors in Human Immunodeficiency Virus Type 1 mRNA Metabolism, Replication, and InfectivityJournal of Virology, 2009
- Global Analysis of Host-Pathogen Interactions that Regulate Early-Stage HIV-1 ReplicationCell, 2008
- Control of alternative pre-mRNA splicing by Ca++ signalsBiochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms, 2008
- A high-throughput screening strategy identifies cardiotonic steroids as alternative splicing modulatorsProceedings of the National Academy of Sciences of the United States of America, 2008
- Identification of Host Proteins Required for HIV Infection Through a Functional Genomic ScreenScience, 2008
- Gag-Processing Defect of Human Immunodeficiency Virus Type 1 Integrase E246 and G247 Mutants Is Caused by Activation of an Overlapping 5′ Splice SiteJournal of Virology, 2008
- Insights into the selective activation of alternatively used splice acceptors by the human immunodeficiency virus type-1 bidirectional splicing enhancerNucleic Acids Research, 2008
- Utilization of host SR protein kinases and RNA-splicing machinery during viral replicationProceedings of the National Academy of Sciences, 2006
- Manipulation of Alternative Splicing by a Newly Developed Inhibitor of ClksJournal of Biological Chemistry, 2004